Mehmet Bulut1, Muhammet Kazım Erol1, Devrim Toslak1, Melih Akidan1, Ebru Kaya Başar2, Hasan Fatih Çay3. 1. Department of Ophthalmology, Antalya Training and Research Hospital, Antalya, Turkey. 2. Deparment of Animal Science Biometry and Genetics Unit, Akdeniz University, Faculty of Agriculture, Antalya, Turkey. 3. Department of Rheumatology, Antalya Education and Research Hospital, Physical Medicine Rehabilitation, Antalya, Turkey.
Abstract
OBJECTIVES: This study aims to detect hydroxychloroquine (HCQ)-induced retinal toxicity at an earlier stage through the use of spectral-domain optical coherence tomography device, especially by measuring macular retinal ganglion cell-inner plexiform layer (RGC-IPL) thickness. PATIENTS AND METHODS: In this study, 92 eyes of 46 Caucasian female patients (mean age 53.6±8.1 years; range 32 to 69 years) who were taking HCQ were assigned to group 1, while 80 eyes of 40 age-matched Caucasian female control subjects (mean age 56.1±10.7 years; range 34 to 71 years) were assigned to group 2. RGC-IPL thickness and retinal nerve fiber layer thickness were measured in all subjects by Cirrus high-definition optical coherence tomography model 5000 device using macular cube 512¥128 and optic disc cube 200¥200 protocols. We performed an evaluation to see if there was any difference between the measured values of the groups. The correlation between average RGC-IPL thickness measures and cumulative dose of HCQ and duration of use was analyzed. RESULTS: Retinal ganglion cell-inner plexiform layer of group 1 was found to be statistically thinner than that of group 2 both on average and in all segments (superior, superonasal, inferonasal, inferotemporal and superotemporal) except inferior segment when segmented (p<0.05). Additionally, a statistically significant negative correlation was found between the average RGC-IPL thickness and cumulative dose of HCQ (r= -0.371, p=0.001) as well as the duration of use (r= -0.308, p=0.006). CONCLUSION: Patients taking HCQ were found to have decreased RGC-IPL thickness at an early stage due to retinal toxicity induced by the drug. We think that measuring the RGC-IPL thickness may become an important objective in HCQ screening tests.
OBJECTIVES: This study aims to detect hydroxychloroquine (HCQ)-induced retinal toxicity at an earlier stage through the use of spectral-domain optical coherence tomography device, especially by measuring macular retinal ganglion cell-inner plexiform layer (RGC-IPL) thickness. PATIENTS AND METHODS: In this study, 92 eyes of 46 Caucasian female patients (mean age 53.6±8.1 years; range 32 to 69 years) who were taking HCQ were assigned to group 1, while 80 eyes of 40 age-matched Caucasian female control subjects (mean age 56.1±10.7 years; range 34 to 71 years) were assigned to group 2. RGC-IPL thickness and retinal nerve fiber layer thickness were measured in all subjects by Cirrus high-definition optical coherence tomography model 5000 device using macular cube 512¥128 and optic disc cube 200¥200 protocols. We performed an evaluation to see if there was any difference between the measured values of the groups. The correlation between average RGC-IPL thickness measures and cumulative dose of HCQ and duration of use was analyzed. RESULTS: Retinal ganglion cell-inner plexiform layer of group 1 was found to be statistically thinner than that of group 2 both on average and in all segments (superior, superonasal, inferonasal, inferotemporal and superotemporal) except inferior segment when segmented (p<0.05). Additionally, a statistically significant negative correlation was found between the average RGC-IPL thickness and cumulative dose of HCQ (r= -0.371, p=0.001) as well as the duration of use (r= -0.308, p=0.006). CONCLUSION: Patients taking HCQ were found to have decreased RGC-IPL thickness at an early stage due to retinal toxicity induced by the drug. We think that measuring the RGC-IPL thickness may become an important objective in HCQ screening tests.
Authors: N Costedoat-Chalumeau; I Ingster-Moati; G Leroux; C Fardeau; O Benveniste; C Simon; B Bodaghi; J C Piette Journal: Rev Med Interne Date: 2011-11-15 Impact factor: 0.728
Authors: Julio A Rodriguez-Padilla; Thomas R Hedges; Bryan Monson; Vivek Srinivasan; Maciej Wojtkowski; Elias Reichel; Jay S Duker; Joel S Schuman; James G Fujimoto Journal: Arch Ophthalmol Date: 2007-06
Authors: Mehmet Bulut; Melih Akıdan; Onursal Gözkaya; Muhammet Kazım Erol; Ayşe Cengiz; Hasan Fatih Çay Journal: Graefes Arch Clin Exp Ophthalmol Date: 2018-08-29 Impact factor: 3.117